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HSE National Drug Treatment Centre 
Laboratory  
The HSE-NDTC laboratory is the largest specialist 
provider of drugs of abuse screening for drug 
treatment services providing a nationwide service to 
the HSE Addiction Services, hospitals, General 
Practitioners, voluntary organisations, Department of 
Education (juvenile detention centres), the Probation 
Service, the Courts Service, the Medical Council, an 
Bord Altranais and various occupational health 
departments.  
 
Introduction 
In 2013 it was reported that Ireland had the highest 
use of new synthetic drugs in Europe, with 
consumption levels three times the EU average, 
according to the UN Office on Drugs and Crime1 
which that said new psychoactive substances (NPS) 
were "proliferating at an unprecedented rate" across 
the world and posed "unforeseen public health" 
effects.  
 
The Report of the International Narcotics Control 
Board for 2014 2, states that in Europe, the 
availability and abuse of new psychoactive 
substances remain a major public health challenge, 
with a record number of such substances being newly 
identified.  
 
The INCB 2014 Global Synthetic Drugs Assessment3, 
notes that the Eurobarometer survey conducted 
among 12,000 randomly selected youths aged 15-24 
across the EU in 2011 recorded the lifetime 
prevalence of youths that had experimented with 
“legal substances that imitate the effects of illicit 
drugs”. The highest lifetime prevalence rates were 
reported by Ireland at 16.3 per cent. 
 
According to 2014 EMCDDA update4, the data 
suggests that the growth of the market in new 
psychoactive substances will continue to pose a 
range of challenges for public health and drug policy 
over the next few years. Particular challenges relate 
to the speed at which new psychoactive substances 
appear, their open sale and the lack of information 
on their effects and harms. 
 
Due to clinical demand for testing, since 2008 we 
have constantly redeveloped our LCMS capability to 
include several multi-residue testing methods in order 
to meet the challenge of testing for New 
Psychoactive Substances. We have reported on this 
in a number of publications. 6,7,8 
 
This has involved on-going method development over 
this time as more drugs were added to the screen. 
Most recently to unambiguously identify  
all of the different compounds due to common MRM’s 
and presence of multiple isomers, by separating the 
screened compounds into 7 groups and optimizing 
the chromatographic and mass spectrometer 
parameters utilizing MRM’s we can now 
unambiguously identify over 80 compounds in one 
run. 
 
Objective 
The objective of the study is to report on trends in 
New Psychoactive substances over the period 2010-
2015 in samples tested in the NDTC laboratory. 
“Spice” drugs and related synthetic cannabinoids are 
not included in the study. 
 
Materials and Methods 
Analysis was carried our using our in-house screen 
for multiple compounds with 2 transitions for each 
separated in a 21 min gradient.   
Mobile Phase A: 100:100:800 Buffer: ACN: water 
Mobile Phase B: 100:900, buffer: ACN  
Buffer: 0.5% formic acid, 25mM ammonium formate 
 
Targeted analysis included the following drugs:       
2-methylamphetamine, 4-methylamphetamine, BZP,  
MDA, N-Methyl-5 APB, Pentedrone, Camfetamine, 
Ethylone/Butylone, Pentylone, Flurotropacocaine, 
Benzoylecgonine, methamphetamine, p-
methoxyamphetamine, dimethylcathinone, p-
methoxymethamphetamine, 3,4 DMMC, MDAT, Methylone, 
Ketamine, 5-MeO Dalt, Cocaine, 2-Aminoindane, 4-
fluoroamphetamine, Bernzocaine, MDAI, p-FPP, 4-EMC, 
Methedrone, MDEA, 3TFMPP, Desoxypipradol, MDPV, 
Amphetamine, Pseudoephedrine, Ethcathinone, 3-
fluoromethcathinone, MDMA, MPBP, Benzedrone, 
Dimethocaine, 3-methylamphetamine, 3-methiopropamine, 
synephrine, Mephedrone, 2-fluoromethcathinone, 4-MEC, 
MPPP, PVP, 5-IAI, Naphyrone, 4-methylamphetamine, 
methcathinone, 5-APB, Buphedrone, 4-fluoromethcathinone, 
N,N-4-trimethylcathinone, mCPP, MBDB, PCat, 
methoxetamine, MDPBP, 3,4 MD-N-benzylcathinone, BK-2CB, 
nitracaine, methoxypiperamide, mephtetramine, 25I-NBOMe, 
alpha-methyltryptamine, 2CB, 25B-NBOMe, 2CE, 2CI, 
ethylphenidate, 25C-NBOMe.   
 
Compounds were optimised on the mass spectrometer by 
using the automated compound optimization wizard in 
Analyst software. 
 
Samples were diluted 1/10 in water (dilute n’ shoot) before 
injecting into the LC/MS for analysis. 
 
Figure 1: Examples of NPS packaging found in 
Headshops in Ireland 
 
 
 
Instrumentation 
LCMS 
The ABSciex 3200 QTrap method uses Electrospray positive 
ionisation with multi-reaction monitoring - 2 MRM transitions 
for each compound tested coupled with Enhanced Product 
Ion monitoring (EPI) giving full scan data.   This is coupled to 
an Agilent 1100 series HPLC. The column used was an 
Agilent Poroshell SB 120 C18 coupled with an Agilent 
Poroshell SB120 UHPLC Guard column. 
 
Samples 
Urine samples were obtained from participants in a 
methadone maintenance program screened on a regular basis 
for drug and alcohol use by immunoassay. 
Samples are tested for NPS on request where use of these 
drugs is suspected. We have also carried out a number of 
random “sweeps”.  
 
 Table 1: Top  NPS drugs detected by year 
 
2010 2011 2012 2013 2014 2015
2 Methylone (5%) PVP (7.3%) MDPBP (8.16%) Mephedrone (4.12%) PVP (7.9%) Pentedrone (3.89%)
3 MDPV (4.22%) MDAI (2.33%) PVP (5.1%) Methylone(3.71%)
4-methyl 
ethcathinone (5.91%)
MDPBP (1.17%)
4 MDPBP (3.85%) MDPV (2.04%)
N-Ethyl 
cathinone(3.06%)
PVP (3.71%) 5-APB (4.04%)
5
Butylone/ Ethylone 
(3.68%)
3TFMPP (1.67%) Benzocaine (2.38%)
N-Methyl-5 APB 
(2.47%)
MDPBP (1.14%)
8
4-methyl ethcathinone 
(1.92%)
4-methyl ethcathinone 
(1.48%)
Dimethocaine  
(0.68%)
Pentedrone (1.33%)
BZP (0.23%);                    
3,4 DMMC (0.23%)
1
4-methyl 
ethcathinone 
(12.24%)
Pentedrone (9.1%) PVP (5.84%)
6 BZP (2.63%) Dimethocaine (1.63%) Methylone (1.7%) Benzocaine (2.15%) Mephedrone (0.91%)
Mephedrone(13.95%) MDPBP (12.62%)
4-methyl ethcathinone 
(11.75%)
Buphedrone (2.56%)
Fluorotropacocaine 
(1.55%)
3-TFMPP (1.02%)
MDPV (0.45%); 
Methoxetamine 
(0.45%)
4-Fluoromethcathinone 
(1.95%)
9 3-TFMPP (1.84%) Mephedrone (1.48%)
Ketamine (0.34%); 
BZP (0.34%)
MDPV (1.24%)
Benzocaine (0.23%); 
mCPP(0.23%)
10
N-Ethyl cathinone 
(1.58%)
N-Ethyl cathinone 
(1.11%)
N-Ethyl cathinone 
(0.82%)
7
 
Results: 
It can be seen from the data in Table 1 that the profile of 
drugs has changed over time due to the effect of various 
legislation enacted both here and in Europe. Mephedrone 
which was the most widely used drug in 2010 (13.95%) 
 
had a usage of 0.91% by 2014.  Pentedrone was seen 
at 1.33% in 2013 and was up to 9.1% in 2014. 4-MEC 
was the NPS of choice in 2012 and 2013 with 12.24 
and 11.75% seen respectively. 
 
Discussion/Conclusion 
Poly drug use is prevalent in the addiction population 
is seen in many drug related deaths4. We have seen 
that these new psychoactive substances are used 
within the addiction services cohort.  
 
As evidenced elsewhere in Europe banning specified 
drugs promoted a game of “Cat and Mouse” whereby 
as drugs were banned suppliers were racing to 
produce new drugs to meet demand. A study we 
conducted in January 2010 of random Methadone 
maintenance patient urine samples for Methylone, 
Mephedrone and BZP found that 13.9% were positive 
for Mephedrone, 3.3% for Methylone, and 0.5% for 
BZP.  In 2011 MDPBP and PVP emerged on the scene 
as use of banned drugs reduced. 2012 saw the arrival 
of 4-MEC with a 122% usage rate.  4-MEC was still 
the most popular in 2013.  Pentedrone arrived in 
2013, and by 2014 was the most popular at 9.1%, 
PVP was a close second at 8.1%.  So far in 2015 PVP 
and Pentedrone are the NPS’s of choice. 
 
The profile of drugs has changed greatly over the 
years as various legislative measures were introduced 
and this is reflected in the drugs detected by us in 
patient samples6,7,8. 
 
In terms of the main cathinones seized in 2013 in 
Europe 3-MMC (341 kg), 4-MEC (201 kg), pentedrone 
(197 kg) and alpha-PVP (115 kg) accounted for 
almost 80 % of the total amount seized. Between 
2008 and 2013 there has been a 60-fold increase in 
the number of seizures of synthetic cathinones.9 
 
In Ireland in 2013, the main NPS drugs (excluding  
synthetic cannabinoids) seized in Ireland were PVP, 4-
MEC, Methylone, MDPBP and Fluoroamphetamine.10 
This correlates with our findings. The data 
demonstrates the on-going challenges in monitoring 
the use of these dangerous new substances and 
keeping up with the new drugs as they emerge.  
 
A serious problem for testing laboratories is the long 
time it takes to get certified reference standards for 
new drugs which emerge. 
 
Acknowledgements 
L.Lawlor, M.Kehoe, A.Shine, S.Philbin, J.Hannon, E. Burke, 
G.Gaynor, G.Smith, S.Conroy,    
 
References 
1. http://www.unodc.org/unodc/secured/wdr/wdr2013/
World_Drug_Report_2013.pdf 
2. http://www.incb.org/incb/en/publications/annual-
reports/annual-report-2014.html 
3. http://www.unodc.org/documents/scientific/2014_Glo
bal_Synthetic_Drugs_Assessment_web.pdf 
4. Health Research Board (2014) Drug-related deaths 
and deaths among drug users in Ireland: 2011 figures 
from the National Drug-Related Deaths Index. 
5. http://www.emcdda.europa.eu/attachements.cfm/att_
235958_EN_TD0415135ENN.pdf 
6. McNamara, S.  1-Benzylpiperazine Abuse amongst 
Attendees of the Drug Treatment Centre Board.  Irish 
Medical Journal 2009, June:102(6):191 
7. McNamara S, Stokes S, Coleman N.  Head Shop 
Compound abuse amongst attendees of The Drug 
Treatment Centre Board.  Ir Med J. 2010 May; 103 
(5):134,136-7. 
8. O’Byrne P, Pierce V. Kavanagh P, McNamara S and 
Stokes, S.  Screening of Stimulants Including Designer 
Drugs in Urine Using a Liquid Chromatography 
Tandem Mass Spectrometry System. Journal of 
Analytical Toxicology 2013;37:64–73 
9. New Psychoactive substances in Europe; An update 
from the EU Early Warning System March 2015 
http://www.emcdda.europa.eu/attachements.cfm/att_
235958_EN_TD0415135ENN.pdf  
10. http://www.garda.ie/Documents/User/Annual%20Rep
ort%202013%20-%20English.pdf 
 
 
